What question did this study set out to answer?

The aim is to investigate the association of TROP2 NMR assessed by QCS with clinical outcomes in EGFR-mutated NSCLC patients treated with Dato-DXd.

March 21, 2026ESMO OpenOpen Access

42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

View Full Paper

Ask AI

Bookmark

The aim is to investigate the association of TROP2 NMR assessed by QCS with clinical outcomes in EGFR-mutated NSCLC patients treated with Dato-DXd.
Conducted a pooled analysis from TROPION-Lung05 and TROPION-Lung01 trials.
Evaluated TROP2 NMR status using quantitative continuous scoring (QCS).
Included patients with EGFR mutations receiving Dato-DXd and osimertinib.
TROP2 NMR was significantly associated with improved clinical outcomes in treated patients.
Findings support the role of TROP2 NMR as a potential biomarker for treatment response.
Results may help in optimizing treatment strategies for EGFRm NSCLC.

Implication

Analysis shows relationship between TROP2 NMR and clinical outcomes in EGFR-mutated NSCLC, suggesting potential for improved treatment strategies.

Abstract

Background: Dato-DXd received accelerated US FDA approval for treatment of EGFRm NSCLC based on a pooled analysis of EGFRm cohorts from TROPION-Lung05 (TL05; NCT04484142) and TROPION-Lung01 (TL01; NCT04656652).TROP2 NMR status by QCS was associated with clinical outcomes with Dato-DXd in patients (pts) with non-squamous, non-actionable genomic alteration (NSQ non-AGA) NSCLC who were treated in TL01 and TROPION-

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sands et al. (2026) studied this question.

synapsesocial.com/papers/69be35166e48c4981c6733f5 https://doi.org/10.1016/j.esmoop.2026.106349

View Full Paper

Ask AI

Bookmark

Implication

Analysis shows relationship between TROP2 NMR and clinical outcomes in EGFR-mutated NSCLC, suggesting potential for improved treatment strategies.

42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

Key Points

Implication

Abstract

Discussion

Cite This Study

42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading